Cronos Group (NASDAQ:CRON) Stock Crosses Below 50 Day Moving Average - What's Next?

Cronos Group logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • Cronos Group shares fell below their 50-day moving average of $3.32 on Monday, trading as low as $3.25 and last at $3.27.
  • Analysts have a consensus “Buy” rating (one Strong Buy, three Buy, one Hold), with a reported average price target of $2.30.
  • In its latest quarter, Cronos reported EPS of $0.04 versus $0.03 expected, while revenue of $63.45 million topped analysts’ $51.15 million estimate.
  • MarketBeat previews top five stocks to own in December.

Cronos Group Inc. (NASDAQ:CRON - Get Free Report) passed below its 50-day moving average during trading on Monday. The stock has a 50-day moving average of $3.32 and traded as low as $3.25. Cronos Group shares last traded at $3.27, with a volume of 911,176 shares changing hands.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently weighed in on CRON shares. Zacks Research raised Cronos Group from a "hold" rating to a "strong-buy" rating in a research note on Thursday, October 22nd. Weiss Ratings upgraded Cronos Group from a "buy (b-)" rating to a "buy (b)" rating in a report on Thursday, October 8th. TD Securities reaffirmed a "buy" rating on shares of Cronos Group in a research report on Monday, September 28th. Finally, Wall Street Zen raised Cronos Group from a "hold" rating to a "buy" rating in a report on Saturday, November 7th. One investment analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating and one has given a Hold rating to the company. According to data from MarketBeat, Cronos Group currently has a consensus rating of "Buy" and a consensus target price of $2.30.

Read Our Latest Research Report on CRON

Cronos Group Stock Down 3.3%

The firm has a market cap of $1.20 billion, a price-to-earnings ratio of 19.24 and a beta of 0.96. The company has a 50-day moving average price of $3.32 and a 200 day moving average price of $2.90.

Cronos Group (NASDAQ:CRON - Get Free Report) last announced its quarterly earnings data on Thursday, November 5th. The company reported $0.04 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.03 by $0.01. The business had revenue of $63.45 million during the quarter, compared to analyst estimates of $51.15 million. Cronos Group had a return on equity of 2.56% and a net margin of 28.04%. Equities analysts forecast that Cronos Group Inc. will post 0.16 EPS for the current year.

Institutional Inflows and Outflows

Several hedge funds have recently bought and sold shares of the company. Cibc World Market Inc. bought a new position in Cronos Group during the second quarter valued at approximately $3,820,000. Pillsbury Lake Capital LLC acquired a new stake in Cronos Group in the second quarter valued at approximately $2,252,253. Parallax Volatility Advisers L.P. bought a new stake in Cronos Group in the second quarter worth approximately $834,000. Bank of America Corp DE bought a new stake in Cronos Group in the second quarter worth approximately $438,000. Finally, Legal & General Group Plc bought a new stake in Cronos Group in the second quarter worth approximately $485,000. 8.71% of the stock is owned by institutional investors and hedge funds.

Cronos Group Company Profile

(Get Free Report)

Cronos Group is a cannabinoid company that develops, produces, and markets cannabis and cannabis-derived products. Its business includes cultivation, processing, product development, and distribution. The company sells products in categories such as dried cannabis flower, pre-rolls, vaporizers, edibles, and extracts. Its brand portfolio includes Spinach and PEACE NATURALS. Founded in 2012 and headquartered in Toronto, Cronos serves consumers in Canada and select international markets, including Israel.

Featured Articles

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Cronos Group Right Now?

Before you consider Cronos Group, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Cronos Group wasn't on the list.

While Cronos Group currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

7 Blue-Chip Stocks to Add To Your Forever Portfolio Cover

A strong long-term portfolio starts with companies that can survive recessions, inflation, changing consumer habits, and shifting market leadership.

This report names seven blue-chip stocks across technology, retail, consumer staples, healthcare, networking, sporting goods, and utilities that offer investors a mix of stability, income, growth, and staying power.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines